20D0 Stock Overview
Operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Cidara Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.30 |
| 52 Week High | US$26.20 |
| 52 Week Low | US$9.20 |
| Beta | 0.86 |
| 1 Month Change | 7.02% |
| 3 Month Change | -16.06% |
| 1 Year Change | n/a |
| 3 Year Change | 106.45% |
| 5 Year Change | -71.23% |
| Change since IPO | -93.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| 20D0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 10.2% | -0.6% | 0.8% |
| 1Y | n/a | -12.3% | 14.6% |
Return vs Industry: Insufficient data to determine how 20D0 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 20D0 performed against the German Market.
Price Volatility
| 20D0 volatility | |
|---|---|
| 20D0 Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 20D0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 20D0's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 38 | Jeff Stein | www.cidara.com |
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials.
Cidara Therapeutics, Inc. Fundamentals Summary
| 20D0 fundamental statistics | |
|---|---|
| Market cap | €244.75m |
| Earnings (TTM) | -€166.46m |
| Revenue (TTM) | €270.86k |
1,095x
P/S Ratio-1.8x
P/E RatioIs 20D0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 20D0 income statement (TTM) | |
|---|---|
| Revenue | US$302.00k |
| Cost of Revenue | US$72.10m |
| Gross Profit | -US$71.80m |
| Other Expenses | US$113.79m |
| Earnings | -US$185.59m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.31 |
| Gross Margin | -23,774.83% |
| Net Profit Margin | -61,454.97% |
| Debt/Equity Ratio | 0% |
How did 20D0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 05:22 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cidara Therapeutics, Inc. is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Timothy Chiang | BTIG |
| Chiara Russo | Cantor Fitzgerald & Co. |
| Eric Schmidt | Cantor Fitzgerald & Co. |